Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100
Debt
Debt-to-Equity Ratio0.67
Current Ratio1.66
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio25.33
Forward P/E Ratio21.99
P/E Growth1.83
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales4.05
Cash Flow$4.7861 per share
Price / Cash13.23
Book Value$17.87 per share
Price / Book3.54
Profitability
EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins3.13%
Return on Equity15.19%
Return on Assets6.57%
Miscellaneous
Employees99,000
Outstanding Shares1,753,190,000
Market Cap$111,011.86
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, June 8th. Stockholders of record on Friday, July 13th will be given a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date is Thursday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, July, 18th. The healthcare product maker reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.02. The healthcare product maker had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.71 billion. Abbott Laboratories had a net margin of 3.13% and a return on equity of 15.19%. The company's quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY18 earnings guidance on Wednesday, July, 18th. The company provided earnings per share guidance of $2.85-2.91 for the period, compared to the Thomson Reuters consensus estimate of $2.86. Abbott Laboratories also updated its Q3 guidance to $0.73-0.75 EPS.
What price target have analysts set for ABT?
18 analysts have issued 12-month price objectives for Abbott Laboratories' shares. Their forecasts range from $64.00 to $80.00. On average, they expect Abbott Laboratories' stock price to reach $69.75 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price. View Analyst Ratings for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 63)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
- Mr. Robert B. Ford, Exec. VP of Medical Devices (Age 44)
- Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 39)
Has Abbott Laboratories been receiving favorable news coverage?
Media coverage about ABT stock has trended somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abbott Laboratories earned a news impact score of 0.20 on Accern's scale. They also assigned news coverage about the healthcare product maker an impact score of 49.55 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.12%), Swedbank (0.09%), Retirement Systems of Alabama (0.09%), Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%) and Cornerstone Wealth Management LLC (0.05%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Hartford Investment Management Co., Bank of Montreal Can, Stralem & Co. Inc., Palo Capital Inc., Deprince Race & Zollo Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH and Rathbone Brothers plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was purchased by a variety of institutional investors in the last quarter, including Swedbank, Cornerstone Wealth Management LLC, Atalanta Sosnoff Capital LLC, Dalton Greiner Hartman Maher & Co., Contravisory Investment Management Inc., Whittier Trust Co., State of Alaska Department of Revenue and Calamos Advisors LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $63.32.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $111.01 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
